PARIS--(BUSINESS WIRE)--Regulatory News:
Pixium Vision (Paris:PIX) (FR0011950641 - PIX), a company developing innovative bionic vision systems to allow patients who have lost their sight to lead more independent lives, today announced its scientific program with multiple presentations of clinical and pre-clinical results at the Association for Research in Vision and Ophthalmology (ARVO) 2017 world congress in Baltimore 7 – 11 May, the main annual event for research and innovation in ophthalmology. The presentations consist in 4 poster presentations and 3 podium talks, including IRIS® retinotopic performance in human and latest insights into PRIMA’s pre-clinical performance and safety results.
Regarding the IRIS® epi-retinal bionic vision system, results showed a highly significant correlation (p<0.001) between electrode stimulation position and perceived phosphene flash location in patient’s visual field. These results from the IRIS® clinical study allow definition of stimulation strategies aiming to provide clinical benefit with the IRIS® system.
Regarding the PRIMA wireless sub-retinal photovoltaic implant, the multiple presentations include results from the Vision Institute in Paris, demonstrating positive behavioural response via elicited visual perception with PRIMA implant in living non-human primates. Moreover, Stanford University team also presents positive behavioural results with prosthetic vision mediated by PRIMA implant in rats with retinal degeneration. These new pre-clinical data sets further strengthen Pixium Vision’s file for first-in-human studies which is being assessed by regulatory bodies.
Khalid Ishaque, CEO of Pixium Vision, said: “We are delighted to share the excellent advances made with both IRIS® and PRIMA, our two retinal bionic vision systems, with the global vision research community at ARVO. The research results with IRIS® in clinical study continue to add to clinical experience for improving patient outcomes and supporting commercialization activities following its regulatory approval in Europe. For PRIMA, our tiny wireless photovoltaic implant, the latest pre-clinical results presented at ARVO provide even greater support in planning and on-going dialogue with the regulatory bodies for the first human studies.”
The presentations on IRIS® and PRIMA include:
Retinotopy of percepts elicited by an IRIS®
V. Bismuth et al.
Poster board #: B0546; Abstract Number: 4190 - B0546
Behavioral and electrophysiological characterization of
photovoltaic subretinal implants in non-human primates
P-H. Prevot et al.
Presentation Abstract Number: 4270 Paper Session Wed, May 10 - 12:30 – 12:45 Hall G
Behavioral assessment of photovoltaic subretinal prosthesis in
rats with retinal degeneration
H. Lorach et al.
Poster board #: B0558; Abstract Number: 4202 - B0558
Photovoltaic Subretinal Prosthesis with Pixel Sizes Down to 40 um
E. Ho et al.
Presentation Abstract Number: 4269 Paper Session Wed, May 10 - 12:15 – 12:30 Hall G
Retinal spatiotemporal characteristics and contrast sensitivity
with subretinal prosthesis
X. Lei et al.
Poster board #: B0539; Abstract Number: 4183 - B0539
Optimization of pillar electrodes in subretinal prosthesis for
enhanced proximity to target neurons
T. Flores et al.
Poster board #: B0556; Abstract Number: 4200 - B0556
Animal studies of subretinal approach to prosthetic restoration
Retinitis pigmentosa: Novel treatments and challenges Room 314 Sat, May 6 – 1:00pm – 4:30pm
To view Pixium Vision related abstracts please click here: ARVO2017
Next event: Annual General Meeting – June 27th, 2017
About ARVO, the Association for Research in Vision and Ophthalmology: http://www.arvo.org/
ABOUT PIXIUM VISION: www.pixium-vision.com